An Observational Study of Adherence to Anastrozole in Early Breast Cancer Treatment
Completed
- Conditions
- Breast Cancer
- Registration Number
- NCT00737009
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of this study is to describe adherence to anastrozole treatment current practice: cases where anastrozole treatment was halted ( timescale and causes) and estimate the proportion of postmenopausal women with early breast cancer who continue anastrozole therapy after one year follow-up.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 259
Inclusion Criteria
- Postmenopausal woman with early breast cancer who are prescribed with anastrozole as adjuvant endocrine therapy under the routine clinical practice.
- Histologically or cytologically proven to be HR+(ER or PR +)
- No other concomitant endocrine therapy such as estrogen therapy or selective estrogen receptor modulators
- Provision of written informed consent
Read More
Exclusion Criteria
- Recurrence of breast cancer
- Known hypersensitivity to anastrozole or to any of its excipients
- Any severe concomitant condition which makes it undesirable for the patient to participate in the trial or which would jeopardize adherence with the trial protocol: Amenorrhea<12 months and a intact uterus; Previous inclusion in the present study; Participation in a other clinical study during the last 30 days·
- Women who does not agreed to participate the program
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To describe adherence to anastrozole treatment current practice: cases where anastrozole treatment was halted ( timescale and causes) every 3- 6 months (4 visit in one year)
- Secondary Outcome Measures
Name Time Method Describe menopausal symptoms every 3- 6 months (4 visit in one year) Estimate the proportion of postmenopausal women with early breast cancer who continue anastrozole therapy after one year follow-up every 3- 6 months (4 visit in one year) Identify predictors of non- adherence every 3- 6 months (4 visit in one year) The proportion of DFS after 1 year follow-up every 3- 6 months (4 visit in one year)
Trial Locations
- Locations (1)
Research Site
🇻🇳Hue, Vietnam